Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1
Others Struggle To Raise Ratio
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
You may also be interested in...
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.